Switching haemophilia products and inhibitor risk: a United States' perspective

E-ISSN： 1600-0609|94|4|283-283

ISSN： 0902-4441

Source： EUROPEAN JOURNAL OF HAEMATOLOGY, Vol.94, Iss.4, 2015-04, pp. : 283-283

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Switching treatments in haemophilia: is there a risk of inhibitor development?

EUROPEAN JOURNAL OF HAEMATOLOGY, Vol. 94, Iss. 4, 2015-04 ,pp. : 284-289

John Wiley & Sons Inc

Access to resources Recommend Favorite

The 2000 United Kingdom Haemophilia Centre Doctors’ Organisation (UKHCDO) Inhibitor Guidelines

Pathophysiology of Haemostasis and Thrombosis, Vol. 32, Iss. 1, 2002-05 ,pp. : 19-21

Karger

Access to resources Recommend Favorite

A large‐scale computational study of inhibitor risk in non‐severe haemophilia A

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 168, Iss. 3, 2015-02 ,pp. : 413-420

John Wiley & Sons Inc

Access to resources Recommend Favorite

Risk factors associated with inhibitor development in Chinese patients with haemophilia B

HAEMOPHILIA, Vol. 21, Iss. 4, 2015-07 ,pp. : e286-e293

John Wiley & Sons Inc

Access to resources Recommend Favorite

Cost-effective osteoporosis treatment thresholds: the United States perspective

By Tosteson A. Melton L. Dawson-Hughes B. Baim S. Favus M. Khosla S. Lindsay R.

Osteoporosis International, Vol. 19, Iss. 4, 2008-04 ,pp. : 437-447

Springer Publishing Company

Access to resources Recommend Favorite